Autobahn Labs Announces Key Licensing Milestones in Alliances with Early University Partners

PALO ALTO, CA, USA, November 14, 2023 – Autobahn Labs, an early-stage drug discovery incubator, announced today that it had executed exclusive license agreements to foundational technologies in its collaborations with the Los Angeles and San Francisco campuses of the University of California. The objective of Autobahn’s collaborations with its academic partners is to identify academic research programs targeting important unmet medical needs and to advance their commercialization in companies it launches.